Molecular chaperone therapy- the future in cancer by Abdul Shehzad et al.
Shehzad et al. Infectious Agents and Cancer 2012, 7:20
http://www.infectagentscancer.com/content/7/1/20LETTER TO THE EDITOR Open AccessMolecular chaperone therapy- the future in
cancer
Abdul Moid Shehzad*, Om Dawani, Shehryar Munir and Syed Anas HussainMolecular chaperone or heat shock proteins (HSP) are
vital proteins that increase cell survival by allowing it to
combat stress caused by injurious stimuli through cer-
tain cyto-protective mechanisms [1]. These cyto-
protective mechanisms of molecular chaperones, espe-
cially HSP 90 [2], have a negative effect designated to
favor tumor growth and metastasis among breast cancer,
leukemia, pancreatic and ovarian cancer [3,4].
Stabilization of the structure of important agents in
malignant transformation, such as kinases (Src and Met
tyrosine kinases) and transcription factors (e.g., hypoxia
inducible factor, HIF1) allows molecular chaperones to
stimulate angiogenesis by promoting endothelial cell
proliferation and permitting growth of cancer beyond
the oxygen capacity of tissue diffusion [5]. Molecular
chaperones disrupt the programmed cell death pathway
(apoptosis) by inducing mutant forms of tumor growth
suppressors and DNA repair proteins (p53 and MSH2)
[6-8]. New multi-target antineoplastic drugs like Gelda-
namycin, purine scaffold inhibitors, and Radicicol [9]
have been developed to oppose all such activity of mo-
lecular chaperones.
The new therapeutic agents or Heat Shock Protein
inhibitors function by blocking the intrinsic ATPase
activity of molecular chaperones allowing oncogenic
proteins (Raf-1, Akt/PKB, ErbB2, Cdk4, Polo-1, Met)[10]
to be targeted by the ubiquitin proteasome pathway due
to no chaperone protection [2,9]. An example is the
positive result of the phase II clinical trial of HER2 posi-
tive breast cancer being treated by Hsp90 inhibitor 17-
AAG followed with Trastuzumab [11]. Although direc-
ted towards distinct molecular targets, HSF inhibitors
also inhibit other multiple cancer promoting signaling
pathways, increasing the efficacy in treatment [12]. Syn-
ergistically usage of these new molecular chaperone inhi-
bitors with standard chemotherapeutic drugs had
positive results of tumor cell apoptosis and significant* Correspondence: moid.shehzad91@gmail.com
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reproduction in any medium, provided the orregression in treatment of leukemia and breast cancer
respectively [13],
Despite effective results in phase 1 of clinical trials
[14], HSP inhibitors cause reduction in stress-adaptive
responses of normal cells leading to apoptosis [1].
Depletion of C2C12 (for muscle cell survival) by Gelda-
namycin derivatives [15] and colon adenocarcinoma
growth during 17AAG treatment are some of the exam-
ples of this adverse effect [16]. However, greater affinity
of HSP inhibitors towards tumoral chaperones specifi-
cally, is a reason that many clinical trials have not
reported this side effect, for example 17AAG has 100
times greater affinity for tumoral versus normal cell
HSP90 [1,17].
Although still in phase 2 of clinical trial, the develop-
ment of HSP inhibitors provides an exciting alternative
for molecular-based therapy in cancer [18]. HSP inhibi-
tors like Gantespib, have shown a more promising future
with a broader spectrum against various malignancies
and better safety advantages in comparison to first and
second generations HSP inhibitors [19]. Overall the
advanced mechanism-based use of HSP inhibitors, both
alone and in combination with other drugs, should help
in the improvement of treatment of multiple forms of
cancer in the future with minimal side effects.
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